Reinterpreting the Mechanism of Inhibition of *Mycobacterium tuberculosis* D-Alanine:D-Alanine Ligase by D-Cycloserine

Gareth A. Prosser and Luiz Pedro S. de Carvalho*

Mycobacterial Research Division, MRC National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, U.K.

**Supporting Information**

**ABSTRACT:** D-Cycloserine is a second-line drug approved for use in the treatment of patients infected with *Mycobacterium tuberculosis*, the etiologic agent of tuberculosis. The unique mechanism of action of D-cycloserine, compared with those of other clinically employed antimycobacterial agents, represents an untapped and exploitable resource for future rational drug design programs. Here, we show that D-cycloserine is a slow-onset inhibitor of MtDdl and that this behavior is specific to the *M. tuberculosis* enzyme orthologue. Furthermore, evidence is presented that indicates D-cycloserine binds exclusively to the C-terminal D-alanine binding site, even in the absence of bound D-alanine at the N-terminal binding site. Together, these results led us to propose a new model of D-alanine:D-alanine ligase inhibition by D-cycloserine and suggest new opportunities for rational drug design against an essential, clinically validated mycobacterial target.

D-Cycloserine [DCS, (R)-4-amino-1,2-oxazolidin-3-one (Scheme 1)] is an antibiotic currently employed as the cornerstone of treatment options for multiresistant and extensively drug resistant tuberculosis. DCS is a structural analogue of D-alanine [D-Ala (Scheme 1)] and blocks bacterial growth by inhibiting two enzymes involved in D-Ala metabolism and peptidoglycan biosynthesis: alanine racemase and D-alanine:D-alanine ligase (Ddl). The molecular targets and mechanism of action of DCS are unique among all classes of antibiotics that are currently known, and congruently, DCS displays no cross-resistance with any other front- or second-line antitubercular drugs. This feature of DCS, along with low reported levels of clinical resistance, makes DCS a valuable asset in the antituberculosis compound arsenal. Host toxicity (principally neuronal NMDA receptor partial agonism), however, remains a serious and dose-limiting side effect of DCS treatment. Nonetheless, understanding the inhibitory mechanisms and molecular interactions between DCS and its microbial targets could aid future endeavors in the rational design of improved, next-generation antimycobacterial compounds.

We have previously characterized the steady-state kinetics of DCS inhibition of *Mycobacterium tuberculosis* Ddl (MtDdl). Ddl catalyzes the ATP-dependent formation of the amide bond between two D-alanine molecules, forming the peptidoglycan precursor dipeptide D-alanyl-D-alanine (D-Ala-D-Ala). Ddl catalysis proceeds through two half-reactions, and the two participating D-Ala molecules occupy distinct regions of the active site (N- and C-termini binding sites). As such, DCS can potentially inhibit binding of either D-Ala molecule to Ddl, and steady-state kinetic data from us and others support this hypothesis.

During routine spectrophotometric analysis of MtDdl activity, we noticed that individual time courses of DCS-containing reactions exhibited transient biphasic curvature suggestive of slow-onset inhibition. Although this phenomenon was disregarded for our initial steady-state kinetic analysis of DCS-containing reactions exhibited transient biphasic curvature suggestive of slow-onset inhibition. Although this phenomenon was disregarded for our initial steady-state kinetic analysis of DCS inhibition, the potential significance of this observation motivated us to investigate it further; our findings are reported herein.

**Scheme 1. Structures of D-Alanine and D-Cycloserine**

![Image of D-alanine and D-cycloserine structures]

Received: June 28, 2013
Revised: September 12, 2013
Published: September 13, 2013
Materials. All chemicals were reagent or analytical grade and sourced as previously described. Solutions of DCS were prepared in CHES buffer (pH 9.0) and aliquots stored indefinitely at −80 °C. Aliquots were thawed directly before being used and discarded after 24 h.

Protein Purification. Recombinant MtDdl was overexpressed and purified as a hexahistidine tag fusion protein, as previously described. The gene encoding Escherichia coli DdlB (EcDdl) was amplified via polymerase chain reaction from E. coli BL21 genomic DNA and cloned into the NdeI and SacI sites of pET28a+. E. coli BL21 was transformed with the resulting vector, and the recombinant enzyme was overexpressed and purified in a manner identical to that of MtDdl. Proteins were stored indefinitely at −20 °C in 20 mM TEA (pH 7.8) containing 50% (v/v) glycerol. Proteins were >95% pure as judged by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (results not shown).

Kinetic Measurements. Steady-state kinetics and equilibrium binding were performed as previously described. Time courses for the measurement of slow-onset inhibition were collected on an SX20 stopped-flow spectrometer (Applied Photophysics) at 37 °C, using a 10 mm path-length cell. Data points were recorded every 0.1 s. Catalysis was detected by the same coupled enzyme mechanism as used previously for steady-state kinetic measurements. All reaction mixtures contained 50 mM HEPES (pH 7.3), 10 mM MgCl₂, 80 mM KCl, 3 mM ATP, 0.25 mM NADH, 1.5 mM PEP, and a 40 μM pyruvate kinase/lactate dehydrogenase enzyme solution (PK-ATP, 0.25 mM NADH, 1.5 mM PEP, and 40 μL/mL pyruvate kinase/lactate dehydrogenase enzyme solution (PK-LDH); stock solution of 600 μM PK, 900–1400 units/mL LDH). MtDdl was employed at concentrations from 60 to 290 nM and EcDdl at a final concentration of 30 nM. DCS and D-Ala concentrations were varied as required. Reaction components were sorted into two syringes, with rapid mixing of 60 μL from each starting each reaction. For all assays, both syringes contained HEPES, MgCl₂, KCl, NADH, PEP, and PK-LDH. MtDdl and D-Ala were always stored in separate syringes. For analysis of slow-onset inhibition at the C-terminal D-Ala binding site (i.e., for data for Figure 1), DCS and Mt/EcDdl were stored in separate reaction mixtures prior to the commencement of the reaction. For analysis of slow-onset inhibition at the N-terminal D-Ala site (i.e., for data for Figure 2), MtDdl and DCS (with or without ATP) were stored in the same reaction mixture (for at least 4 min) prior to the commencement of the reaction.

Individual time course data were fit using eq 1

\[
\frac{[P]}{[E]} = \frac{v_i - v_f}{k_{obs}} (1 - e^{-k_{obs}t})
\]

where \([P]/[E]\) is the product formed at time \(t\), \([E]\) is the total MtDdl concentration, \(v_i\) is the initial rate, \(v_f\) is the final (steady-state) rate, and \(k_{obs}\) is the apparent rate constant for approach to the steady state. Time courses were performed in triplicate and \(k_{obs}\) values averaged for each DCS and D-Ala concentration tested. Secondary replots of \(k_{obs}\) versus DCS concentration were fit using eq 2

\[
k_{obs} = k_{-2} + \frac{k_{1}[I]}{1 + |S|/K_m}
\]

where \([I]\) is the DCS concentration, \([S]\) is the D-Ala concentration, and \(k_1\) and \(k_{-2}\) are rate constants as described in Scheme 2. The \(K_m\) value was that for the C-terminal site (4 mM), as previously reported.

**Scheme 2. Minimal Kinetic Mechanism Describing Slow-onset Inhibition without Slow Conformational Changes**

**pH Dependence.** \(K_{DCS}\) and \(K_{Ala}\) pH profile data were fit using eq 3, describing the involvement of two acidic (unresolvable \(pK_a\) values) and two basic (unresolvable \(pK_a\) values) residues in ligand binding:

\[
pK_x = pK_{x0} - \log_{10}\left(\frac{1 + H/K_{a1}}{1 + H/K_{a2}}\right) \left(1 + \frac{K_{a1}^2}{H} + \frac{K_{a2}^2}{H^2}\right)
\]

where \(pK_{x0}\) is the negative \(\log_{10}\) of the parameter being measured (\(K_{DCS}\) or \(K_{Ala}\)), \(pK_x\) is the \(pH\)-independent value of the parameter being measured, \(H\) is the proton concentration, and \(K_{a1}\) and \(K_{a2}\) are acid dissociation constants for enzyme or ligand ionizable groups. One-dimensional NMR data indicated that DCS was stable and consisted of a single chemical species across all pHs tested over the time frame of the experiment (data not shown).

**Software.** All data analysis, curve fitting, and graph design were performed with SigmaPlot 12.0. Reported values and errors were derived from software-assisted regression analyses of averaged replicate (at least triplicate) data sets.

**RESULTS AND DISCUSSION**

Using stopped-flow spectrophotometry to guarantee sufficient sampling and the accuracy of the crucial early time points (first 0–20 s), we generated high-resolution time course data for MtDdl activity at multiple concentrations of DCS and D-Ala (Figure 1A). To simplify the kinetic analysis, all D-Ala concentrations tested were saturating for the N-terminal D-Ala binding site (i.e., for data shown). MtDdl and DCS were stored in separate reaction mixtures prior to the commencement of the reaction. For analysis of slow-onset inhibition at the C-terminal D-Ala binding site (i.e., for data for Figure 2), MtDdl and DCS (with or without ATP) were stored in the same reaction mixture (for at least 4 min) prior to the commencement of the reaction.

Individual time course data were fit using eq 1

\[
\frac{[P]}{[E]} = \frac{v_i - v_f}{k_{obs}} (1 - e^{-k_{obs}t})
\]

where \([P]/[E]\) is the product formed at time \(t\), \([E]\) is the total MtDdl concentration, \(v_i\) is the initial rate, \(v_f\) is the final (steady-state) rate, and \(k_{obs}\) is the apparent rate constant for approach to the steady state. Time courses were performed in triplicate and \(k_{obs}\) values averaged for each DCS and D-Ala concentration tested. Secondary replots of \(k_{obs}\) versus DCS concentration were fit using eq 2

\[
k_{obs} = k_{-2} + \frac{k_{1}[I]}{1 + |S|/K_m}
\]

where \([I]\) is the DCS concentration, \([S]\) is the D-Ala concentration, and \(k_1\) and \(k_{-2}\) are rate constants as described in Scheme 2. The \(K_m\) value was that for the C-terminal site (4 mM), as previously reported.
could lead to formation of new species with differing affinities for MtDdl. Similarly, other resonant or dimerized forms of DCS may exist under certain conditions and influence inhibition parameters (Scheme S1 of the Supporting Information). We therefore checked the stability of DCS by one-dimensional and $^{13}$C HSQC NMR in the presence and absence of enzyme (and other buffer components) and found no spectral changes between the two conditions (Figures S1 and S2 of the Supporting Information). Furthermore, liquid chromatography–mass spectrometry analysis of reaction products of MtDdl, $\alpha$-Ala, DCS, and ATP failed to reveal MtDdl-dependent DCS modifications (data not shown). We therefore conclude that a single, stable DCS species is responsible for the slow-onset behavior observed with MtDdl.

Slow-onset inhibition has not previously been reported for DCS with any Ddl orthologue. Therefore, to test if the behavior we observed is unique to MtDdl, or if similar behavior in prior studies had been missed, we overexpressed, purified, and assessed the activity of recombinant E. coli DdlB (EcDdl), an enzyme for which DCS inhibition data are available. Steady-state kinetic analysis revealed $k_{cat}$, $k_{m,D-Ala}$, and $K_{i,DCS}$ values consistent with previous reports (Table S1 of the Supporting Information). More importantly, progress curves for reaction mixtures containing DCS were nonlinear, although with a substantially smaller curvature (Figure 1B). Accordingly, rate constants calculated from these data (Table 1) were considerably different from those of MtDdl; EcDdl displayed a >3-fold faster rate of association of the enzyme–inhibitor complex ($k_1$) and a 10-fold faster rate of dissociation of the enzyme–inhibitor complex ($k_{-1}$). These results suggest that although DCS displays slow-onset inhibition against both EcDdl and MtDdl, the response is substantially more prolonged, and therefore more mechanistically significant, for MtDdl.

On the basis of the magnitude of the dissociative half-life alone (48 s), it is difficult to conceive a strong physiological effect for the slow-onset behavior of DCS against MtDdl; however, theoretical calculations provide a DCS–MtDdl complex residence time up to 8 orders of magnitude longer than that for the $\alpha$-Ala–MtDdl complex (Supporting Information and Figure S3), suggesting a significant and substantial contribution of slow-onset binding to enzyme activity in its physiological setting, and may indeed partially account for the observed narrow-spectrum activity of DCS against M. tuberculosis. With an increasing significance of drug–enzyme residence times in drug discovery ventures, these results emphasize the importance of DCS as a functional scaffold for future MtDdl-targeted drug design experiments.

A complementary technique for confirming slow-onset inhibition is to preincubate enzyme with inhibitor prior to the commencement of the reaction. Time-dependent dissociation of the enzyme–inhibitor complex produces a characteristic “lag” phase at the beginning of the time course before equilibration to a steady-state rate. This method is impossible to apply to the study of slow-onset inhibition of DCS at the C-terminal $\alpha$-Ala binding site of MtDdl, as preincubation would require both ATP and $\alpha$-Ala (the substrate for the N-terminal site), generating a kinetically competent enzyme complex in the process. Instead, by preincubating MtDdl with only ATP and DCS prior to the commencement of the reaction, we were able to investigate whether slow-onset inhibition occurs at the N-terminal $\alpha$-Ala binding site. Figure 2 shows time courses of MtDdl activity following preincubation with DCS and ATP, or

---

**Table 1. Kinetic Parameters for Slow-Onset Inhibition of MtDdl and EcDdlB by DCS**

| Parameter | MtDdl | EcDdl |
|-----------|-------|-------|
| $k_{cat}$ (M$^{-1}$ s$^{-1}$) | 888 ± 36 | 2976 ± 360 |
| $k_{m,D-Ala}$ (s$^{-1}$) | 0.014 ± 0.003 | 0.13 ± 0.03 |
| $t_{1/2}$ (s) | 48 | 5 |

*Values and errors were derived from regression analyses of averaged replicate (at least triplicate) data sets. Components with which the enzyme was preincubated prior to the commencement of the reaction. Reaction composition listed in Materials and Methods. Only 0.75 mM $\alpha$-Ala ($\approx K_{m,Ala}$) tested for EcDdl.*
with just DCS. A lag period was evident when both ATP and DCS were included in the preincubation mixture, but not when ATP was absent, reiterating the importance of ATP in DCS binding.4 In conclusion, binding and dissociation of DCS with both the MtDdl−ATP and the MtDdl−ATP−D-Ala complexes can be described by a slow-onset mechanism. Equations 1 and 2 were used on relevant progress curve data to calculate rate constants for DCS binding and dissociation from the MtDdl−ATP complex (Table 1 and Figure S4 of the Supporting Information). We were surprised at the similarity of these values to those obtained for DCS inhibition at the C-terminal D-Ala binding site (2-fold difference between $k_2$ and $k_{-2}$ values), especially when compared with the differences in active site architecture, D-Ala affinities, and substrate specificities between the two distinct substrate binding pockets.4,16–18 Together with our previous data demonstrating similar (also unexpected) DCS affinity at each binding site ($K_{i,DCS1}$ and $K_{i,DCS2}$ of 15 and 25 μM, respectively), and in the absence of any published Ddl−DCS cocrystal structure to claim otherwise, we now propose a novel mechanism of DCS inhibition whereby only the C-terminal D-Ala binding site of Ddl is capable of binding DCS but can be occupied either in the presence or in the absence of bound N-terminal D-Ala (Scheme 3). This theory is entirely consistent with previous steady-state kinetic data from our group and other research groups4,6 as such studies are able to distinguish only between enzyme forms (as per the definition of a competitive inhibitor19); no positional information is derived. It can also explain the inability of two DCS molecules to simultaneously occupy each binding site, as we have previously shown.4 Although structural data are required to definitively assess the true binding mechanism, we were able to lend further support to the proposed mechanism by comparing pH profiles of dissociation constants of the MtDdl−ATP complex and DCS (using intrinsic tryptophan fluorescence quenching) with those of $K_{i,DCS2}$ (binding or inhibition of DCS to the MtDdl−ATP−D-Ala complex). As the active site residues that constitute the chemically distinct binding pockets do not share the same pKa values,20 the almost superimposing pH profile curves shown in Figure 3 refute a model involving separate binding sites for the two DCS binding events.

In summary, our DCS inhibition results indicate that MtDdl binds DCS slowly, resulting in slow-onset inhibition kinetics, contrary to what has been observed for other orthologues. More importantly, the magnitude of the rate constants obtained

Scheme 3. Representation of the Uninhibited Kinetic Mechanism (1), the DCS-Inhibited Forms Proposed To Exist with MtDdl (2 and 3), and Forms That Are Not Likely To Exist (4)
in the presence and absence of d-Ala and the similarities observed in pH studies of DCS dissociation and inhibition strongly suggest that DCS inhibition is attained by DCS binding solely at the C-terminal d-Ala site. This information is of paramount importance for the rational development of improved analogues of DCS that can be used to treat human tuberculosis. In particular, enhanced drug target residence time, of paramount importance for the rational development of DCS, D-cyloserine; Ddl, D-alanine:D-alanine ligase; D-Ala-D-Ala, D-alanyl-D-alanine ligase, which are target enzymes of D-cycloserine. (1) Caminero, J. A., Sotgiu, G., Zumla, A., and Migliori, G. B. (2010) Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. *Lancet Infect. Dis.* 10, 621–629.

(2) Strominger, J. L., Ito, E., and Threnn, R. H. (1960) Competitive inhibition of enzymatic reactions by oxamycin. *J. Am. Chem. Soc.* 82, 998–999.

(3) Yew, W. W., Wong, C. F., Wong, P. C., Lee, J., and Chau, C. H. (1993) Adverse neurological reactions in patients with multidrug-resistant pulmonary tuberculosis after coadministration of cycloserine and ofloxacin. *Clin. Infect. Dis.* 17, 288–289.

(4) Prosser, G. A., and de Carvalho, L. P. (2013) Kinetic mechanism and inhibition of *Mycobacterium tuberculosis* d-alanine–d-alanine ligase by the antibiotic D-cycloserine. *FEBS J.* 280, 1150–1166.

(5) Mullins, L. S., Zawadzke, L. E., Walsh, C. T., and Raushel, F. M. (1990) Kinetic evidence for the formation of d-alanyl phosphate in the mechanism of d-alanyl–d-alanine ligase. *J. Biol. Chem.* 265, 8993–8998.

(6) Neuhaus, F. C., and Lynch, J. L. (1964) The Enzymatic Synthesis of d-Alanyl-d-Alanine. 3. On the Inhibition of d-Alanyl-d-Alanine Synthetase by the Antibiotic D-Cycloserine. *Biochemistry* 3, 471–480.

(7) Morrison, J. F., and Walsh, C. T. (1988) The behavior and significance of slow-binding enzyme inhibitors. *Adv. Enzymol. Relat. Areas Mol. Biol.* 61, 201–301.

(8) Lassen, F. O., and Stammer, C. H. (1971) Cycloserine Dimer Hydrolysis and Its Equilibration with Cycloserine. *J. Org. Chem.* 36, 2631–2634.

(9) Bugg, T. D., Dutka-Malen, S., Arthur, M., Courvalin, P., and Walsh, C. T. (1991) Identification of vancomycin resistance protein VanA as a d-alanine–d-alanine ligase of altered substrate specificity. *Biochemistry* 30, 2017–2021.

(10) Liu, S., Chang, J. S., Herberg, J. T., Hong, M. M., Tomich, P. K., Lin, A. H., and Marotti, K. R. (2006) Allosteric inhibition of *Staphylococcus aureus* d-alanine–d-alanine ligase revealed by crystallographic studies. *Proc. Natl. Acad. Sci. U.S.A.* 103, 15178–15183.

(11) Noda, M., Kawahara, Y., Ichikawa, A., Matoba, Y., Matsu, H., Lee, D. G., Kumagai, T., and Sugiyama, M. (2004) Self-protection mechanism in *cycloserine*-producing *Streptomyces lavendulae*. Gene cloning, characterization, and kinetics of its alanine racemase and d-alanyl-d-alanine ligase, which are target enzymes of *cycloserine*. *J. Biol. Chem.* 279, 44143–46152.

(12) Zawadzke, L. E., Bugg, T. D., and Walsh, C. T. (1991) Existence of two d-alanine–d-alanine ligases in *Escherichia coli* Cloning and sequencing of the dddA gene and purification and characterization of the DdIA and DdLB enzymes. *Biochemistry* 30, 1673–1682.

(13) Copeland, R. A., Pompliano, D. L., and Meek, T. D. (2006) Drug-target residence time and its implications for lead optimization. *Nat. Rev. Drug Discovery* 5, 730–739.

(14) Lu, H., England, K., am Ende, C., Truglio, J. J., Luckner, S., Reddy, B. G., Marlenee, N. L., Knudson, S. E., Knudson, D. L., Bowen, R. A., Kisker, C., and Tonge, P. J. (2009) Slow-onset inhibition of the FabI enoyl reductase from *Staphylococcus aureus* by the antibiotic D-cycloserine. *Antimicrob. Agents Chemother.* 53, 994–999.

(15) Swinney, D. C. (2004) Biochemical mechanisms of drug action: What does it take for success? *Nat. Rev. Drug Discovery* 3, 801–808.

(16) Bruning, J. B., Murillo, A. C., Chacon, O., Barletta, R. G., and Sacchettini, J. C. (2011) Structure of the *Mycobacterium tuberculosis* d-alanine–d-alanine ligase, a target of the antituberculosis drug *cycloserine*. *Antimicrob. Agents Chemother.* 55, 291–301.

(17) Fan, C., Moews, P. C., Walsh, C. T., and Knox, J. R. (1994) Vancomycin resistance: Structure of *d*-alanine–*d*-alanine ligase at 2.3 Å resolution. *Science* 266, 439–443.

(18) Neuhaus, F. C. (1962) The enzymatic synthesis of *d*-alanyl-*d*-alanine. II. Kinetic studies on *d*-alanyl-*d*-alanine synthetase. *J. Biol. Chem.* 237, 3128–3135.

(19) Cook, P. F., and Cleland, W. W. (2007) *Enzyme Kinetics and Mechanism*, pp 121–123, Garland Science, New York.

(20) Carlson, H. A., Briggs, J. M., and McCammon, J. A. (1999) Calculation of the pKₐ values for the ligands and side chains of *Escherichia coli* *d*-alanine–*d*-alanine ligase. *J. Med. Chem.* 42, 109–117.